Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Trial Profile

Open label study to confirm effectiveness, safety and pharmacokinetics of fentanyl transdermal matrix patch, in Japanese patients with cancer pain who have had a minimum amount of morphine therapy, such as equal to less than 45 mg/day of oral morphine or oxycodone equal to less than 30 mg/day

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2011

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Cancer pain
  • Focus Therapeutic Use
  • Most Recent Events

    • 15 Nov 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top